BD Announces Q1 2026 Results and Finalizes Biosciences and Diagnostic Solutions Business Combination

Details

GAAP and adjusted diluted earnings per share (EPS) were $1.34 and $2.91, respectively. The company finalized the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, expected to close on the same day. BD also affirmed its fiscal 2026 revenue growth guidance and provided an adjusted diluted EPS guidance for the new BD. The combination is anticipated to drive shareholder value by intensifying focus on commercial capabilities, innovation, and productivity.

Items reported

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.